Apixaban in AVERROES points the way to excellent alternatives to warfarin

Dr Seth Bilazarian


August 31, 2010

This feature requires the newest version of Flash. You can download it here.
Afib patients taking apixaban
had a 54% lower risk of stroke and systemic embolic events compared to those taking aspirin as reported in the AVERROES trial. With RE-LY
fresh in our minds and in anticipation of the results of ROCKET-AF
, ARISTOTLE, and ENGAGE-HF, the future looks bright for better alternatives to warfarin. What are your thoughts about this trial and its implications for clinical practice?


AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding

RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib

RE-LY: Patient preference based on the data


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.